(ARMP) Armata Pharmaceuticals, Inc. Business Model Canvas Research

Armata Pharmaceuticals, Inc. depends on manufacturing and CMC partners because bacteriophage drugs need tight process control for scale-up, formulation, and release testing. These partners keep clinical supply moving and are a key step toward future commercial readiness for a platform still in the clinical stage.

• Scale-up support
• Formulation expertise
• Release testing capacity
• Clinical supply continuity
• Commercial readiness

Academic and infectious-disease experts are key to Armata Pharmaceuticals, Inc. because phage programs depend on university and physician-scientist input for pathogen biology, resistance mapping, and translational trial design. In a niche field with few approved options, these ties also lift scientific credibility and can speed Phase 1/2 study planning.

• Better pathogen and resistance insight
• Stronger translational study design
• Higher trust in a niche field

Armata Pharmaceuticals, Inc. must keep tight regulatory and quality controls around its biotech work, including complete study records, adverse-event reporting, and cGMP/CMC (chemistry, manufacturing, and controls) discipline. These steps keep investigational use moving and build the package regulators need for future approval.

• Keep FDA-ready documentation current
• Report safety events on time
• Maintain cGMP and CMC standards

Partner management is central to Armata Pharmaceuticals, Inc.’s model: the Merck collaboration requires clear joint research scope, milestone tracking, and tight intellectual-property boundaries. Business development matters too, because new partnerships can bring non-dilutive funding and lower reliance on equity raises.

• Manage joint R&D scope.
• Track milestones and IP limits.
• Pursue non-dilutive funding.

Armata Pharmaceuticals, Inc. relies on deep microbiology, translational science, and clinical development skills to move its 2 lead phage programs from lab data into human trials. Regulatory expertise matters even more for novel biologics like phages, where CMC and FDA path design can make or break the program.

• 2 lead phage programs
• Turns research into trials
• Critical for FDA filings

Armata Pharmaceuticals, Inc. keeps its main offices in Marina del Rey, California, and uses the site as its central base for corporate management, research coordination, and partner engagement. That matters because Armata ended fiscal 2025 with a lean operating footprint, so one hub helps keep decision-making and collaboration tight.

• Central operating base
• Supports research coordination
• Enables partner engagement

Armata Pharmaceuticals, Inc. is beyond discovery: it has two lead programs in clinical development, so it can generate real human safety and efficacy data instead of only preclinical signals. That makes the platform more credible for partners, physicians, and investors because clinical proof is harder to copy and far more decision-useful.

• Two lead clinical programs
• Human data beats lab data
• Raises partner and investor trust

Armata Pharmaceuticals, Inc.’s Merck collaboration extends its synthetic phage platform beyond today’s lead assets and into next-gen bacteriophage candidates, widening the addressable infectious-disease pipeline. It signals a clear path to more programs if the partnership keeps converting platform science into clinic-ready candidates.

• Broadens beyond lead assets
• Targets more infectious diseases
• Supports partnered pipeline growth

Armata Pharmaceuticals, Inc. uses scientific advisory interaction to educate clinicians on phage therapy and refine trial design with microbiology and infectious disease experts. This matters in a market still shaped by limited clinical precedent, and Armata’s 2 lead programs, AP-SA02 and AP-PA02, depend on tight scientific exchange to improve study quality and adoption readiness.

• Expert input strengthens trial design
• Supports phage-therapy education
• Improves market and clinician understanding

As a public biotech, Armata Pharmaceuticals, Inc. must keep shareholders and analysts informed on trial milestones, partnership news, and cash use, because these updates shape access to capital and market trust. In 2025, that meant regular disclosure through SEC filings and investor calls around AP-SA02 and AP-PA02 progress and runway management.

• Trial updates drive investor confidence.
• Partnership news signals external validation.
• Cash-use disclosure supports funding access.

Peer-reviewed medical publications help Armata Pharmaceuticals, Inc. validate its phage-based infection platform and build trust with clinicians who rely on published evidence before using new anti-infective tools. In infection-focused medicine, even a small number of strong clinical or preclinical papers can lift reputation and support later partnering or trial uptake.

• Validates novel science
• Builds clinician trust
• Supports infection-area adoption

Armata Pharmaceuticals, Inc. uses public-company disclosures as a formal investor channel, with earnings updates, press releases, and SEC filings such as Form 10-K, 10-Q, and 8-K. For a Nasdaq-listed biotech, that visibility is critical for capital markets access, partner trust, and timely risk signaling.

• 10-K, 10-Q, 8-K disclosures
• Earnings updates and press releases
• Supports investor and partner reach

Patients with resistant infections are the core end users for Armata Pharmaceuticals, Inc., especially those with bloodstream and lung infections caused by multidrug-resistant bacteria. The unmet need is biggest in severe disease: the CDC estimates 2.8 million antibiotic-resistant infections and 35,000 deaths each year in the U.S.

• Bloodstream and lung infections
• High need in severe cases
• Targets resistant organisms

Universities and research hospitals are key users and collaborators for Armata Pharmaceuticals, Inc., because they help test phage biology, clinical utility, and translational fit in a field where evidence is still being built. Their role matters most in early human data, protocol design, and peer-reviewed validation.

• Evaluate phage activity and safety
• Support clinical evidence generation
• Help build credibility in a niche market

General and administrative expenses cover Armata Pharmaceuticals, Inc.’s corporate overhead: management, finance, legal, SEC reporting, and other public-company compliance. Its Marina del Rey headquarters also adds occupancy and admin costs, so this line item supports the enterprise structure even when no programs are advancing.

• Management and compliance overhead
• Headquarters occupancy and admin costs
• Supports public-company structure

Armata Pharmaceuticals, Inc. must fund collaboration duties, IP work, and regulatory filings to advance novel phage assets. These costs cover consulting, legal review, and trial documentation, and they sit alongside heavy R&D spending; Armata reported $22.2 million in research and development expense in 2024.

These partner and regulatory costs are fixed enough to shape cash burn, but they are essential for moving assets through IND and later FDA review.

• Consulting and legal review
• IP protection and filings
• Regulatory submissions and records

Armata Pharmaceuticals, Inc. can tap infectious-disease grants and sponsored studies as non-dilutive funding, which helps offset heavy R&D burn before product sales. In FY2025, this kind of revenue is most valuable pre-commercially because it can fund labs, animal studies, and early clinical work without adding debt or equity dilution.

• Offsets pre-commercial R&D spend
• Supports grant-funded trial work
• Reduces dilution pressure

If AP-SA02, AP-PA02, or AP-PA03 win approval, Armata Pharmaceuticals, Inc. could earn direct product sales, starting in hospital-led settings where serious bacterial infections are treated. This stream stays binary: it depends on clean clinical results and regulatory approval, not on current revenue, because Armata Pharmaceuticals, Inc. has not yet commercialized these assets.

• Approval unlocks direct product revenue
• Hospital markets likely launch first
• Clinical and FDA outcomes drive value